搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Bifidobacterium longum 50S ribosomal protein L18 (rplR) CSB-YP464879BTA
CSB-EP464879BTA
CSB-BP464879BTA
CSB-MP464879BTA
CSB-EP464879BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum 50S ribosomal protein L17 (rplQ) CSB-YP464880BTA
CSB-EP464880BTA
CSB-BP464880BTA
CSB-MP464880BTA
CSB-EP464880BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Ribosomal RNA small subunit methyltransferase H (rsmH) CSB-YP464881BTA
CSB-EP464881BTA
CSB-BP464881BTA
CSB-MP464881BTA
CSB-EP464881BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum UDP-N-acetylmuramate--L-alanine ligase (murC), partial CSB-YP464882BTA
CSB-EP464882BTA
CSB-BP464882BTA
CSB-MP464882BTA
CSB-EP464882BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum DNA-directed RNA polymerase subunit omega (rpoZ) CSB-YP464883BTA
CSB-EP464883BTA
CSB-BP464883BTA
CSB-MP464883BTA
CSB-EP464883BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Holliday junction ATP-dependent DNA helicase RuvB (ruvB) CSB-YP464884BTA
CSB-EP464884BTA
CSB-BP464884BTA
CSB-MP464884BTA
CSB-EP464884BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Prolipoprotein diacylglyceryl transferase (lgt), partial CSB-YP464885BTA1
CSB-EP464885BTA1
CSB-BP464885BTA1
CSB-MP464885BTA1
CSB-EP464885BTA1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Chorismate synthase (aroC) CSB-YP464886BTA
CSB-EP464886BTA
CSB-BP464886BTA
CSB-MP464886BTA
CSB-EP464886BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Bifunctional protein GlmU (glmU) CSB-YP464887BTA
CSB-EP464887BTA
CSB-BP464887BTA
CSB-MP464887BTA
CSB-EP464887BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Arginine repressor (argR) CSB-YP464888BTA
CSB-EP464888BTA
CSB-BP464888BTA
CSB-MP464888BTA
CSB-EP464888BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Pyridoxal biosynthesis lyase pdxS (pdxS) CSB-YP464889BTA
CSB-EP464889BTA
CSB-BP464889BTA
CSB-MP464889BTA
CSB-EP464889BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Non-canonical purine NTP pyrophosphatase (BLD_1030) CSB-YP464890BTA
CSB-EP464890BTA
CSB-BP464890BTA
CSB-MP464890BTA
CSB-EP464890BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Ribosome maturation factor RimM (rimM) CSB-YP464891BTA
CSB-EP464891BTA
CSB-BP464891BTA
CSB-MP464891BTA
CSB-EP464891BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bifidobacterium longum Glutamyl-tRNA (Gln) amidotransferase subunit A, partial CSB-YP464892BTA
CSB-EP464892BTA
CSB-BP464892BTA
CSB-MP464892BTA
CSB-EP464892BTA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylacidiphilum infernorum Transcriptional repressor NrdR (nrdR) CSB-YP464893MSV
CSB-EP464893MSV
CSB-BP464893MSV
CSB-MP464893MSV
CSB-EP464893MSV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylacidiphilum infernorum D-tyrosyl-tRNA (Tyr) deacylase CSB-YP464894MSV
CSB-EP464894MSV
CSB-BP464894MSV
CSB-MP464894MSV
CSB-EP464894MSV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylacidiphilum infernorum Potassium-transporting ATPase C chain (kdpC), partial CSB-YP464895MSV1
CSB-EP464895MSV1
CSB-BP464895MSV1
CSB-MP464895MSV1
CSB-EP464895MSV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylacidiphilum infernorum NADH-quinone oxidoreductase subunit D (nuoD) CSB-YP464896MSV
CSB-EP464896MSV
CSB-BP464896MSV
CSB-MP464896MSV
CSB-EP464896MSV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylacidiphilum infernorum Isoleucine--tRNA ligase (ileS), partial CSB-YP464897MSV
CSB-EP464897MSV
CSB-BP464897MSV
CSB-MP464897MSV
CSB-EP464897MSV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methylacidiphilum infernorum 30S ribosomal protein S15 (rpsO) CSB-YP464898MSV
CSB-EP464898MSV
CSB-BP464898MSV
CSB-MP464898MSV
CSB-EP464898MSV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>